N-γ-acrylamidobutyric acid hydroxysuccinimidyl ester | 63406-07-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-γ-acrylamidobutyric acid hydroxysuccinimidyl ester
• 英文别名: (2,5-Dioxopyrrolidin-1-yl) 4-(prop-2-enoylamino)butanoate
• CAS: 63406-07-5
• 化学式: C₁₁H₁₄N₂O₅
• 分子量: 254.243
• InChiKey: OJRRZIYQMANSFB-UHFFFAOYSA-N

物化性质

• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  92.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-γ-acrylamidobutyric acid hydroxysuccinimidyl ester 、 L-Tyr(t-Bu)-Ot-Bu 以 二氯甲烷 为溶剂， 以87%的产率得到tert-butyl (2S)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]-2-[4-(prop-2-enoylamino)butanoylamino]propanoate
  参考文献：
  名称：

  带有RGD的生物相容性端粒的合成和初步生物学评估。

  摘要：

  本文报道的工作涉及一类新的生物相容性端粒载体的合成和初步生物学评估，所述载体具有作为肿瘤细胞靶向的肽RGDSK序列和以125I标记的酪氨酸部分作为体内探针。将这些端粒静脉注射到带有嫁接的B16同基因黑素瘤的小鼠体内后，在几个组织中获得的放射性水平表明，在端粒结构中添加RGD残基后，其对肿瘤周围高度血管化区域的亲和力增加。

  DOI：

  10.1016/s0960-894x(02)00079-3
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 4-[(1-氧代-2-丙烯-1-基)氨基]丁酸 在 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 以47%的产率得到N-γ-acrylamidobutyric acid hydroxysuccinimidyl ester
  参考文献：
  名称：

  In vitro and in vivo evaluations of THAM derived telomers bearing RGD and Ara-C for tumour neovasculature targeting

  摘要：

  As an approach to the development of specific drug delivery systems, a new class of low macromolecular carriers called 'telomers' endowed with an antitumour agent, such as arabinofuranosylcytosine (Ara-C), RGDSK peptidic sequences, as tumour targeting moieties, and tyrosine groups labelled with I-125 atoms allowing the in vivo scintigraphic follow up, were synthesized. Their tumour targeting ability was assessed in vivo in mice bearing a murine B16 melanoma. The biological results showed that the presence of RGDSK sequences onto the macromolecules leads to the selective targeting and the accumulation of telomers within the vascularized zone of the tumour. Moreover, such compounds exhibited in vitro a better IC50 (0.015 muM) than pure Ara-C and in vivo an oncostatic index higher than 160%. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(03)00150-8

文献信息

• Synthesis and preliminary biological assessments of RGD bearing biocompatible telomers
  作者：Sylvain Jasseron、Christiane Contino-Pépin、Jean Claude Maurizis、Maryse Rapp、Bernard Pucci

  DOI：10.1016/s0960-894x(02)00079-3

  日期：2002.4

  telomeric carriers bearing peptidic RGDSK sequences as tumor cell targeting and tyrosine moieties labelled with 125I as in vivo probe. The radioactivity levels obtained in several tissues, after the intravenous injections of these telomers in mice bearing grafted B16 syngenic melanoma showed that the addition of a RGD residue to a telomeric structure confers it an increased affinity for the highly vascularized

  本文报道的工作涉及一类新的生物相容性端粒载体的合成和初步生物学评估，所述载体具有作为肿瘤细胞靶向的肽RGDSK序列和以125I标记的酪氨酸部分作为体内探针。将这些端粒静脉注射到带有嫁接的B16同基因黑素瘤的小鼠体内后，在几个组织中获得的放射性水平表明，在端粒结构中添加RGD残基后，其对肿瘤周围高度血管化区域的亲和力增加。
• In vitro and in vivo evaluations of THAM derived telomers bearing RGD and Ara-C for tumour neovasculature targeting
  作者：S. Jasseron、C. Contino-Pépin、J.C. Maurizis、M. Rapp、B. Pucci

  DOI：10.1016/s0223-5234(03)00150-8

  日期：2003.9

  As an approach to the development of specific drug delivery systems, a new class of low macromolecular carriers called 'telomers' endowed with an antitumour agent, such as arabinofuranosylcytosine (Ara-C), RGDSK peptidic sequences, as tumour targeting moieties, and tyrosine groups labelled with I-125 atoms allowing the in vivo scintigraphic follow up, were synthesized. Their tumour targeting ability was assessed in vivo in mice bearing a murine B16 melanoma. The biological results showed that the presence of RGDSK sequences onto the macromolecules leads to the selective targeting and the accumulation of telomers within the vascularized zone of the tumour. Moreover, such compounds exhibited in vitro a better IC50 (0.015 muM) than pure Ara-C and in vivo an oncostatic index higher than 160%. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.